Cumulus Oncology Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative anti-cancer therapies for clinical settings characterized by high unmet medical needs. Established in 2017, the company targets critical pathways in cancer treatment to enhance the efficacy and outcomes of existing and experimental therapies. Cumulus Oncology's lead candidate is a preclinical oral Chk1 kinase inhibitor designed to facilitate DNA repair, thereby improving treatment effectiveness for cancer patients. The company is supported by a team of seasoned professionals and industry partners with extensive experience in drug discovery and development, providing valuable insights into optimal cancer treatment strategies.
Nodus Oncology is a biotechnology company dedicated to developing innovative therapies that target the DNA damage response (DDR) pathways in cancer treatment. The company specializes in creating novel small molecules designed to inhibit specific vulnerabilities within these pathways. By focusing on DDR-targeting therapies, Nodus Oncology aims to provide effective cancer therapeutics that address critical aspects of tumor biology, ultimately enhancing treatment options for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.